Washington University ID-CRU conducts research in several areas such as: HIV treatment, HIV prevention, hepatitis, fungal infections, sexually transmitted diseases, the COVID-19 virus as well as various other general vaccine studies. No matter your health, age, or gender we may have a study for YOU. Here are a few of the studies for which we are currently enrolling.

HIV Clinical Trials


Participants in this study must have an undetectable viral load while on their antiretroviral therapy (ART). The investigational product is called EBT-101, a genome editing treatment. It is given as a single intravenous (IV) infusion.

The sponsor is doing this study to see if EBT-101 will cut out the HIV DNA in cells that are currently being suppressed with ART therapy.

Participants must meet these requirements (among others):

  • Males (sex at birth) age 18 – 60 years on stable ART therapy for at least 2 years
  • Have no other chronic illnesses
  • Are willing and able to attend weekly and sometimes daily visits to your doctor
  • Are willing to pause ART therapy, if eligible, for analytic treatment interruption (ATI).

Study Procedures include:

  • One IV dose of EBT 101
  • Daily visits for the first 14 days after dosing and weekly visits through week 48. Then, follow-up visits twice yearly for the next five years and yearly visits for the following 10 year

The ID-CRU has many more ongoing studies. Also, transportation and monetary compensation are often provided.

These studies can be a great way to move science and healthcare forward while providing you with a chance to become engaged and informed. You will receive quality healthcare, individualized support and an opportunity to make a difference. Anyone can participate and we want you.

If interested please contact us to find out which studies are right for you, call us at 314-454-0058 or email at idcru@wustl.edu.